CL2015002529A1 - Compuestos de tetrahidropirrolotiazina - Google Patents
Compuestos de tetrahidropirrolotiazinaInfo
- Publication number
- CL2015002529A1 CL2015002529A1 CL2015002529A CL2015002529A CL2015002529A1 CL 2015002529 A1 CL2015002529 A1 CL 2015002529A1 CL 2015002529 A CL2015002529 A CL 2015002529A CL 2015002529 A CL2015002529 A CL 2015002529A CL 2015002529 A1 CL2015002529 A1 CL 2015002529A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- tetrahydropyrrolothiazine
- alzheimer
- disease
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Compuestos derivados de tetrahidropirrolotiazina que son inhibidores de la enzima beta-secretasa (BACE) y que presentan penetración al sistema nervioso central. Estos compuestos son útiles para el tratamiento de trastornos mediados por el péptido Abeta, tal como la enfermedad de Alzheimer. Se reivindican los compuestos, la composición farmacéutica que los comprende y el uso de ellos para la prevención y/o el tratamiento de la enfermedad de Alzheimer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361776819P | 2013-03-12 | 2013-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015002529A1 true CL2015002529A1 (es) | 2016-03-28 |
Family
ID=50382615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015002529A CL2015002529A1 (es) | 2013-03-12 | 2015-09-09 | Compuestos de tetrahidropirrolotiazina |
Country Status (38)
| Country | Link |
|---|---|
| US (3) | US8841293B1 (es) |
| EP (1) | EP2970336B1 (es) |
| JP (1) | JP6095844B2 (es) |
| KR (1) | KR101688761B1 (es) |
| CN (1) | CN105026404B (es) |
| AP (1) | AP2015008713A0 (es) |
| AR (1) | AR094918A1 (es) |
| BR (1) | BR112015018738A8 (es) |
| CA (1) | CA2898500C (es) |
| CL (1) | CL2015002529A1 (es) |
| CR (1) | CR20150418A (es) |
| CY (1) | CY1119585T1 (es) |
| DK (1) | DK2970336T3 (es) |
| EA (1) | EA026006B1 (es) |
| ES (1) | ES2653421T3 (es) |
| HK (1) | HK1212694A1 (es) |
| HR (1) | HRP20171851T1 (es) |
| HU (1) | HUE037487T2 (es) |
| IL (1) | IL240903B (es) |
| JO (1) | JO3317B1 (es) |
| LT (1) | LT2970336T (es) |
| MA (1) | MA38390B1 (es) |
| ME (1) | ME02910B (es) |
| MX (1) | MX2015012628A (es) |
| MY (1) | MY180083A (es) |
| NO (1) | NO3039297T3 (es) |
| NZ (1) | NZ712207A (es) |
| PE (1) | PE20151542A1 (es) |
| PH (1) | PH12015502031B1 (es) |
| PL (1) | PL2970336T3 (es) |
| PT (1) | PT2970336T (es) |
| RS (1) | RS56645B1 (es) |
| SG (1) | SG11201507499XA (es) |
| SI (1) | SI2970336T1 (es) |
| TN (1) | TN2015000340A1 (es) |
| TW (1) | TWI593692B (es) |
| UA (1) | UA112941C2 (es) |
| WO (1) | WO2014143579A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2861566T (lt) | 2012-06-13 | 2017-02-10 | F. Hoffmann-La Roche Ag | Nauji diazaspirocikloalkanai ir azaspirocikloalkanai |
| AU2013322838B2 (en) | 2012-09-25 | 2018-02-01 | F. Hoffmann-La Roche Ag | New bicyclic derivatives |
| PT2912041T (pt) | 2012-10-26 | 2017-02-13 | Lilly Co Eli | Inibidores de bace |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| RS56776B1 (sr) | 2013-11-26 | 2018-04-30 | Hoffmann La Roche | Derivati oktahidro-ciklobuta [1,2-c;3,4-c']dipirola kao inhibitori autotaksina |
| TWI684452B (zh) | 2014-03-14 | 2020-02-11 | 美國禮來大藥廠 | 胺基噻嗪化合物 |
| JP6554481B2 (ja) | 2014-03-26 | 2019-07-31 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | オートタキシン（ａｔｘ）及びリゾホスファチジン酸（ｌｐａ）産生の阻害剤としての縮合［１，４］ジアゼピン化合物 |
| EA037928B1 (ru) | 2014-03-26 | 2021-06-08 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa) |
| TWI570127B (zh) * | 2014-09-15 | 2017-02-11 | 美國禮來大藥廠 | 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物 |
| TWI599358B (zh) * | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
| AR103406A1 (es) * | 2015-01-30 | 2017-05-10 | Lilly Co Eli | Sal de tosilato |
| AR103680A1 (es) | 2015-02-23 | 2017-05-24 | Lilly Co Eli | Inhibidores selectivos de bace1 |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| AR104241A1 (es) | 2015-04-29 | 2017-07-05 | Lilly Co Eli | Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos |
| CA2992889A1 (en) | 2015-09-04 | 2017-03-09 | F. Hoffmann-La Roche Ag | Phenoxymethyl derivatives |
| BR112017026682A2 (pt) | 2015-09-24 | 2018-08-14 | Hoffmann La Roche | novos compostos bicíclicos como inibidores de dupla ação de atx/ca |
| RU2018114289A (ru) | 2015-09-24 | 2019-10-24 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения в качестве ингибиторов аутотаксина (atx) |
| WO2017050792A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
| JP6877413B2 (ja) | 2015-09-24 | 2021-05-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二重ａｔｘ／ｃａ阻害剤としての新規な二環式化合物 |
| AR107774A1 (es) | 2016-03-16 | 2018-05-30 | Lilly Co Eli | Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer |
| TWI798751B (zh) | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| MX2019007102A (es) | 2016-12-15 | 2019-12-16 | Amgen Inc | Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso. |
| US10947223B2 (en) | 2016-12-15 | 2021-03-16 | Amgen Inc. | Substituted oxazines as beta-secretase inhibitors |
| AU2017376445B2 (en) * | 2016-12-15 | 2021-09-30 | Amgen Inc. | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use |
| CA3047287A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
| JP7149271B2 (ja) | 2016-12-15 | 2022-10-06 | アムジエン・インコーポレーテツド | β－セクレターゼ阻害剤としての１，４－チアジンジオキシドおよび１，２，４－チアジアジンジオキシド誘導体ならびに使用方法 |
| BR112019019017A2 (pt) | 2017-03-16 | 2020-04-14 | Hoffmann La Roche | compostos heterocíclicos de utilidade como inibidores duplos de atx/ca |
| JP7090099B2 (ja) | 2017-03-16 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | Ａｔｘインヒビターとしての新規二環式化合物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5284957A (en) * | 1992-09-03 | 1994-02-08 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| AU2003219955A1 (en) * | 2002-03-22 | 2003-10-13 | Eli Lilly And Company | Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists |
| WO2006138264A2 (en) * | 2005-06-14 | 2006-12-28 | Schering Corporation | Aspartyl protease inhibitors |
| EP2597087B1 (en) | 2005-10-25 | 2016-03-30 | Shionogi&Co., Ltd. | Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors |
| JP5383483B2 (ja) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | アルツハイマー症治療用医薬組成物 |
| WO2009091016A1 (ja) | 2008-01-18 | 2009-07-23 | Eisai R & D Management Co., Ltd. | 縮合アミノジヒドロチアジン誘導体 |
| CA2721738A1 (en) | 2008-04-22 | 2009-10-29 | Schering Corporation | Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use |
| TWI431004B (zh) * | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Ｂａｃｅ抑制劑 |
| MX2010013256A (es) | 2008-06-13 | 2010-12-21 | Shionogi & Co | Derivado heterociclico que contiene azufre que tiene actividad inhibitoria de beta-secretasa. |
| CN102171221B (zh) | 2008-09-30 | 2013-11-06 | 卫材R&D管理有限公司 | 新的稠合的氨基二氢噻嗪衍生物 |
| AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| JPWO2011071109A1 (ja) | 2009-12-11 | 2013-04-22 | 塩野義製薬株式会社 | アミノ基を有する縮合ヘテロ環化合物 |
| GB201100181D0 (en) | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| GB201101139D0 (en) * | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| GB201101140D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| US9145426B2 (en) | 2011-04-07 | 2015-09-29 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
| WO2012162334A1 (en) | 2011-05-24 | 2012-11-29 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| JO3143B1 (ar) * | 2012-04-03 | 2017-09-20 | Lilly Co Eli | مركبات تتراهيدرو بيرولو ثيازين |
-
2014
- 2014-02-26 TW TW103106569A patent/TWI593692B/zh not_active IP Right Cessation
- 2014-02-27 JO JOP/2014/0061A patent/JO3317B1/ar active
- 2014-02-27 AR ARP140100629A patent/AR094918A1/es unknown
- 2014-03-04 ME MEP-2017-252A patent/ME02910B/me unknown
- 2014-03-04 DK DK14712875.5T patent/DK2970336T3/da active
- 2014-03-04 SG SG11201507499XA patent/SG11201507499XA/en unknown
- 2014-03-04 WO PCT/US2014/020070 patent/WO2014143579A1/en active Application Filing
- 2014-03-04 JP JP2016500566A patent/JP6095844B2/ja active Active
- 2014-03-04 PE PE2015001901A patent/PE20151542A1/es active IP Right Grant
- 2014-03-04 MY MYPI2015703056A patent/MY180083A/en unknown
- 2014-03-04 CA CA2898500A patent/CA2898500C/en not_active Expired - Fee Related
- 2014-03-04 HU HUE14712875A patent/HUE037487T2/hu unknown
- 2014-03-04 EP EP14712875.5A patent/EP2970336B1/en active Active
- 2014-03-04 MA MA38390A patent/MA38390B1/fr unknown
- 2014-03-04 US US14/195,897 patent/US8841293B1/en active Active
- 2014-03-04 PT PT147128755T patent/PT2970336T/pt unknown
- 2014-03-04 SI SI201430430T patent/SI2970336T1/sl unknown
- 2014-03-04 RS RS20171243A patent/RS56645B1/sr unknown
- 2014-03-04 KR KR1020157024588A patent/KR101688761B1/ko active IP Right Grant
- 2014-03-04 AP AP2015008713A patent/AP2015008713A0/xx unknown
- 2014-03-04 LT LTEP14712875.5T patent/LT2970336T/lt unknown
- 2014-03-04 NZ NZ71220714A patent/NZ712207A/en not_active IP Right Cessation
- 2014-03-04 MX MX2015012628A patent/MX2015012628A/es unknown
- 2014-03-04 EA EA201591491A patent/EA026006B1/ru not_active IP Right Cessation
- 2014-03-04 CN CN201480014295.6A patent/CN105026404B/zh active Active
- 2014-03-04 ES ES14712875.5T patent/ES2653421T3/es active Active
- 2014-03-04 PL PL14712875T patent/PL2970336T3/pl unknown
- 2014-03-04 BR BR112015018738A patent/BR112015018738A8/pt not_active Application Discontinuation
- 2014-04-03 UA UAA201508698A patent/UA112941C2/uk unknown
- 2014-08-07 US US14/453,855 patent/US8987254B2/en active Active
- 2014-08-12 NO NO14799063A patent/NO3039297T3/no unknown
-
2015
- 2015-02-19 US US14/626,320 patent/US20150157641A1/en not_active Abandoned
- 2015-08-10 TN TN2015000340A patent/TN2015000340A1/en unknown
- 2015-08-14 CR CR20150418A patent/CR20150418A/es unknown
- 2015-08-27 IL IL240903A patent/IL240903B/en not_active IP Right Cessation
- 2015-09-09 CL CL2015002529A patent/CL2015002529A1/es unknown
- 2015-09-10 PH PH12015502031A patent/PH12015502031B1/en unknown
-
2016
- 2016-01-21 HK HK16100629.1A patent/HK1212694A1/zh not_active IP Right Cessation
-
2017
- 2017-11-09 CY CY20171101177T patent/CY1119585T1/el unknown
- 2017-11-28 HR HRP20171851TT patent/HRP20171851T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015002529A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
| EA201692201A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| CL2018000596A1 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
| EA201692177A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| PH12016501192B1 (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
| CL2017000742A1 (es) | Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue | |
| ECSP17038999A (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
| EA201791259A1 (ru) | Производные пиперидина в качестве ингибиторов hdac1/2 | |
| BR112017008103A2 (pt) | composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo. | |
| EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
| ECSP17010481A (es) | Novedosas pirimidinas 2,5-sustituidas | |
| CL2018001085A1 (es) | Derivados de indolin-2-ona | |
| BR112017017970A2 (pt) | composição de fragrância e combinação de fragrâncias | |
| ZA201901168B (en) | Novel compounds for treating parasitic disease | |
| ECSP17010482A (es) | Novedosas pirimidinas 2,5-sustituidas | |
| UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. | |
| CL2016001763A1 (es) | Antagonistas selectivos de nr2b | |
| MY184366A (en) | Pyrazines modulators of gpr6 | |
| MX2015013048A (es) | Forma cristalina de un compuesto ansiolitico. | |
| CL2015003037A1 (es) | Derivados de triazina | |
| EA201791450A1 (ru) | 3,5-диаминопиразоловые ингибиторы киназы |